ClinicalTrials.gg
RecruitingNCT07407439Updated Feb 12, 2026

Real-world Studies of CDK4/6 Inhibitors

An observational study in Breast Cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Tianjin Medical University Cancer Institute and Hospital · Observational

How we know · 4 judgments

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
245
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 59 studies in Breast Neoplasms by Tianjin Medical University Cancer Institute and Hospital — 34 open to participants now, 34 under way, 1 of them phase 3. Breast Neoplasms · Tianjin Medical University Cancer Institute and Hospital.

Planned enrollment
9th of 16
245 · median 373
Started
2025
with 9 others
Observational
16 of 59
6 open now
Primary completion
2026-06
later than 14 of 33 live
Registered
50th of 59
by date

Among the 59 studies in Breast Neoplasms by Tianjin Medical University Cancer Institute and Hospital, this one is the 9th largest by planned enrollment of the 16 observational ones that give a count, is one of 10 that started in 2025, is one of 16 observational ones, reaches primary completion later than 14 of the 33 other live ones, and was the 50th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

34 of the 59 studies in Breast Neoplasms by Tianjin Medical University Cancer Institute and Hospital are open now, in 3 countries. Recruiting first, the newest first:

28 more — sign in →

By country, each count listing its studies:

All 34 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Breast Neoplasms by Tianjin Medical University Cancer Institute and Hospital, or all of them as a file.
02

Study summary

A single-center, real-world study evaluated the clinical outcomes and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2- advanced breast cancer, and conducted a summary analysis of the clinical treatment options after the progression of CDK4/6 inhibitors.

Read the detailed description

This study aims to collect clinical data and case information from real-world clinical practice of patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors combined with endocrine therapy.

The main research objectives include: 1. To evaluate the differences in efficacy among different CDK4/6 inhibitors combination regimens in advanced patients; 2. To investigate the subsequent treatment options chosen by patients in the real world after progression on CDK4/6 inhibitors, with the aim of constructing a predictive model for the response to subsequent treatments, thereby providing support for clinical decision-making for both doctors and patients in such situations.

The secondary objectives include: 1. To truly reflect the differences in adverse reactions of different CDK4/6 inhibitors in the Chinese population through the collection of laboratory and imaging results; 2. To collect tumor samples or peripheral blood samples from some patients for genomic and transcriptomic analyses, in preparation for translational research on the mechanism of CDK4/6 inhibitors resistance.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Palbociclib
  • Abemaciclib
  • Ribociclib
  • Dalcetrapib
  • CDK4/6 inhibitors
  • CDK4/6 inhibitors resistance
  • HR+/HER2- breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who were diagnosed as HR+/HER2- (as defined by the ASCO/CAP guidelines) advanced breast cancer between March 2022 to March 2025

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years old;
  2. Patients diagnosed with HR+/- (as defined by the ASCO/CAP guidelines) advanced breast cancer who were treated in our hospital from March 2022 to March 2025;
  3. Received CDK4/6 inhibitors (including but not limited to the four currently marketed ones: palbociclib, abemaciclib, ribociclib, and dalpiciclib) as advanced-stage treatment for at least one cycle;
  4. Have complete medical history records, including demographic information, pathological reports, treatment records, laboratory test results, and imaging examination reports, etc.

Exclusion criteria

Exclusion Criteria:

  1. Incomplete medical history data.
  2. Only received CDK4/6 inhibitors monotherapy.
  3. Received CDK4/6 inhibitors as /postoperative adjuvant intensification therapy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
245 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Palbociclib cohort

    Use palbociclib in combination with endocrine therapy as the treatment regimen.

  • Abemaciclib cohort

    Use abemaciclib in combination with endocrine therapy as the treatment regimen.

  • Ribociclib cohort

    Use ribociclib in combination with endocrine therapy as the treatment regimen.

  • Dalcetrapib cohort

    Use dalcetrapib in combination with endocrine therapy as the treatment regimen.

  • Other CDK4/6 inhibitors cohort

    Use other CDK4/6 inhibitors in combination with endocrine therapy (including participation in clinical trials of CDK4/6 inhibitors) as the treatment regimen.

This study also gives PalbociclibStudies of PalbociclibPalbociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., RibociclibStudies of RibociclibRibociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., AbemaciclibStudies of AbemaciclibAbemaciclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. rwPFS1 and rwPFS2

    Real-world progression-free survival (rwPFS1) during treatment with CDK4/6 inhibitors and real-world progression-free survival (rwPFS2) of subsequent treatment lines selected by clinicians after progression on CDK4/6 inhibitor therapy.

    Time frame: 6 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — At the stage of result publication, we will provide the IPD data in accordance with the specific requirements from the ICMJE journal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2026
First posted
Feb 12, 2026
StartActual
Jun 1, 2025
Primary completionEst.
Jun 1, 2026
CompletionEst.
Jun 1, 2027
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07407439
Responsible party
Sponsor
First posted
Feb 12, 2026
Start date
Jun 1, 2025
Primary completion
Jun 1, 2026 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Feb 12, 2026

Study contacts

Yehui Shi, MD
Contact
shiyehui@tjmuch.com
022-23340123-3252
Yiran Si, MD
Contact
022-23340123-3252

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion